Results 211 to 220 of about 278,511 (264)

Telithromycin in Lower Respiratory Tract Infections

Future Microbiology, 2006
Telithromycin is a ketolide, a semisynthetic derivative of the 14-membered ring macrolide antibiotics, with an expanded spectrum of activity relative to macrolides. Its good tissue pharmacokinetic characteristics allows once-daily administration, and it has been successfully employed in lower respiratory tract infections.
F. Blasi, M. Cazzola, P. Tarsia, S. Aliberti, C. Baldessari, V. Valenti   +5 more
openaire   +2 more sources

Viral Infection of the Lower Respiratory Tract

Clinics in Chest Medicine, 1987
This article describes the epidemiology, transmission, and pathophysiology of viral infection of the lower respiratory tract. Current approaches to diagnosis, treatment, and prevention also are discussed.
R M, Rose, P, Pinkston, C, O'Donnell, W A, Jensen   +3 more
openaire   +2 more sources

Lower Respiratory Tract Infections

PharmacoEconomics, 2003
While there is some literature on the cost of specific respiratory infections, much of the existing research focuses only on direct medical treatment costs and does not take into consideration workplace burden due to disability and absenteeism.To evaluate the impact of lower respiratory tract infections (LRTIs) on the workplace, specifically regarding ...
Howard, Birnbaum, Melissa, Morley, Stephanie, Leong, Paul, Greenberg, Gene, Colice   +4 more
openaire   +2 more sources

Enoxacin in lower respiratory tract infections

Journal of Antimicrobial Chemotherapy, 1986
In this open, non-comparative study 45 lower respiratory tract infections were treated with the new 4-quinolone, enoxacin. Special attention was paid to infections caused by Pseudomonas aeruginosa. Pseudomonas infections were treated with 600 mg bd. whereas infections caused by other bacteria were treated with 400 mg enoxacin bd.
Wijnands, WJA, van Griethuysen, AJA, Vree, TB, van Klingeren, B, van Herwaarden, CCA   +4 more
openaire   +3 more sources

Biomarkers in lower respiratory tract infections

Pulmonary Pharmacology & Therapeutics, 2010
This review aims to provide physicians with an overview of the potential of biomarkers to complement existing clinical severity scores and in conjunction with clinical parameters to improve the diagnosis, risk-stratification and management of lower respiratory tract infections (LRTIs). The usefulness of biomarkers for diagnosing LRTIs is still unclear.
F. Blasi, D. Stolz, F. Piffer
openaire   +3 more sources

Cefoperazone in Lower Respiratory Tract Infections

Drugs, 1981
17 hospitalised patients with a wide variety of common lower respiratory tract infections received at least 6 days of intravenous bolus cefoperazone 1.0g 12-hourly. Disease was caused by Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and mixed anaerobes in 1 patient. All isolates were sensitive to cefoperazone.
C J, Woods, R B, Ellis-Pegler
openaire   +2 more sources

Pefloxacin in lower respiratory tract infections

Journal of Antimicrobial Chemotherapy, 1990
To determine the efficacy and safety of pefloxacin in the treatment of lower respiratory tract infections, a multicentre trial involving four departments of respiratory diseases was performed. One hundred and eight patients were admitted to the study: most of them were affected with exacerbations of chronic bronchitis or with pneumonia complicating ...
C, Grassi, E, Catena, G, de Iola, F, Ginesu, M, Gori, M, Lucchini, P, Mangiarotti, E, Micillo, M, Onoscuri, O, Orlandi   +9 more
openaire   +2 more sources

Pharmacotherapy for lower respiratory tract infections

Expert Opinion on Pharmacotherapy, 2014
Bacterial infections play an important role as etiological agents in acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and exacerbations of non-cystic fibrosis (CF) bronchiectasis. In acute bronchitis and asthma exacerbations their role is less well defined than with patients with COPD.
Adamantia, Liapikou, Liapikou, Adamantia, Antoni, Torres, Antonio, Torres   +3 more
openaire   +2 more sources

Lower Respiratory Tract Infections

Infectious Disease Clinics of North America, 2004
Lower respiratory tract infections (LRTIs) are among the most common infections treated by health care providers. They include a variety of infections ranging from mild acute viral bronchitis to life-threatening ventilatorassociated pneumonia. Despite advances in general knowledge concerning such diseases, there remains considerable morbidity and ...
openaire   +2 more sources

Azithromycin and lower respiratory tract infections

Expert Opinion on Pharmacotherapy, 2005
Azithromycin is a macrolide antibiotic that has been structurally modified from erythromycin with an expanded spectrum of activity and improved tissue pharmacokinetic characteristics relative to erythromycin. This allows once-daily administration for 3-5 days of treatment compared with traditional multi dosing 7-10-day treatment regimens.
F. Blasi, M. Cazzola, P. Tarsia, R. Cosentini, S. Aliberti, P. Santus, L. Allegra   +6 more
openaire   +3 more sources